The glycosyltransferase EXTL2 promotes proteoglycan deposition and injurious neuroinflammation following demyelination

Annie Pu 1, Manoj K. Mishra 1, Yifei Dong 1, Samira Ghorbanigazar 1, Erin L. Stephenson 1, Khalil S. Rawji 1, Claudia Silva 1, Hiroshi Kitagawa 2, Stephen Sawcer 3 and V. Wee Yong 1,4*

Abstract

Background: Chondroitin sulfate proteoglycans (CSPGs) are potent inhibitors of axonal regrowth and remyelination. More recently, they have also been highlighted as a modulator of macrophage infiltration into the central nervous system in experimental autoimmune encephalomyelitis, an inflammatory model of multiple sclerosis.

Methods: We interrogated results from single nucleotide polymorphisms (SNPs) lying in or close to genes regulating CSPG metabolism in the summary results from two publicly available systematic studies of multiple sclerosis (MS) genetics. A demyelinating injury model in the spinal cord of exostosin-like 2 deficient (EXTL2 −/−) mice was used to investigate the effects of dysregulation of EXTL2 on remyelination. Cell cultures of bone marrow-derived macrophages and primary oligodendrocyte precursor cells and neurons were supplemented with purified CSPGs or conditioned media to assess potential mechanisms of action.

Results: The strongest evidence for genetic association was seen for SNPs mapping to the region containing the glycosyltransferase exostosin-like 2 (EXTL2), an enzyme that normally suppresses CSPG biosynthesis. Six of these SNPs showed genome-wide significant evidence for association in one of the studies with concordant and nominally significant effects in the second study. We then went on to show that a demyelinating injury to the spinal cord of EXTL2 −/− mice resulted in excessive deposition of CSPGs in the lesion area. EXTL2 −/− mice had exacerbated axonal damage and myelin disruption relative to wild-type mice, and increased representation of microglia/macrophages within lesions. In tissue culture, activated bone marrow-derived macrophages from EXTL2 −/− mice overproduce tumor necrosis factor α (TNFα) and matrix metalloproteinases (MMPs).

Conclusions: These results emphasize CSPGs as a prominent modulator of neuroinflammation and they highlight CSPGs accumulating in lesions in promoting axonal injury.

Keywords: CSPG, Multiple sclerosis, Inflammation, Demyelination, Oligodendrocyte, EXTL2

* Correspondence: vyong@ucalgary.ca
1Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, T2N 4 N1, Calgary, Canada
4University of Calgary, 3330 Hospital Drive, Calgary, Alberta T3A 4X9, Canada
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with focal areas of demyelination induced by aberrant immune activation. Associated with demyelination and inflammation are a multitude of changes in the composition of the CNS extracellular matrix (ECM) (reviewed in [1, 2]); however, changes in ECM are understudied in the context of MS, where lesional alterations are largely undefined [3]. Previous reports have highlighted the deposition of chondroitin sulfate proteoglycans (CSPGs) at the borders of chronic active MS lesions [4]. CSPGs are a class of large, glycosylated proteins present both on cell surfaces and in the extracellular matrix. Lecticans, a subset of ECM CSPGs, homeostatically comprise a significant portion of perineuronal nets as well as the neural interstitial matrix, serving roles in development, plasticity, and neuronal function [5, 6]. Lectican CSPG members are versican, aggrecan, neurocan, and brevican. In demyelinating injury, they are locally upregulated by several cell types and deposited near the injury site [7–13]. CSPGs are potent inhibitors for regenerative processes such as axonal regeneration and remyelination [14–17].

CSPGs were recently identified by our group as a novel regulator of neuroinflammation in a mouse model of MS. In particular, the V1 isoform of versican (in which the core protein consists only of the GAGβ segment) is particularly abundant in inflammatory CNS lesions, and a mixture of lecticans stimulates bone marrow-derived macrophages to produce inflammatory cytokines and proteases [18]. Others have reported that the genetic loss of versican in lung macrophages attenuates their pro-inflammatory response to polyninosine-polyctydilic acid [19].

As CSPGs potentially influence reparative processes in the CNS, it is important to explore approaches to overcome this impediment to regeneration. The biosynthetic process of CSPGs has largely been elucidated [20], and a number of pharmacological inhibitors of CSPG production have been examined for therapeutic effects, such as xylosides and fluorinated analogues that inhibit activity of CSPG biosynthesis enzymes [21, 22]. Following CNS insult, chondroitinase ABC (ChABC)-mediated CSPG digestion improved axonal sprouting, remyelination, and cognitive recovery [14–16, 23–27]. Perturbing CSPG signaling through antagonism of receptors (e.g., leukocyte-common antigen related and protein tyrosine phosphatase σ) also increased the population of alternatively activated macrophages following SCI [25]. However, finding an appropriate approach to removing deposited CSPGs in diffuse or heterogeneous pathology is difficult, and the regulators of CSPG production are understudied. Understanding the regulatory mechanisms of CSPG biosynthesis may provide more insight into limiting CSPG deposition after injury.

We interrogated the summary results from the 2011 MS genome-wide association screen (GWAS) and the 2013 MS Immunochip study (Immunochip 2013) focusing on regions containing genes involved in the metabolism of CSPGs, which led to the identification of the glycosyltransferase exostosin-like 2 (EXTL2) gene. EXT2L is a glycosyltransferase that limits the production of CSPGs by terminating its synthesis [28]. Thus, we asked whether investigating the biology of EXT2L and its effects on CSPG deposition and repair following a demyelinating injury to the spinal cord of mice could provide insights to endogenous targets for limiting CSPG production. Our results in mice with constitutive knock-out of EXT2L (EXTL2−/−) in the lysolecithin model of focal demyelination [29] highlight elevated CSPG deposition in lesions that contribute to the increased recruitment and activation of microglia/macrophages leading to the exacerbation of axonal loss.

Methods

Analyses of MS genetic databases

The MS GWAS performed jointly by the International Multiple Sclerosis Genetics Consortium (IMSGC) and the Wellcome Trust Case Control Consortium (WTCCC2) involved 9772 cases and 17,376 controls collected from across 15 different countries (all individuals were of European descent) [30]. The study generated data from 465,434 autosomal SNPs and identified 29 novel genome-wide significant associations. The MS Immunochip study [31] was a follow-up effort focused on genomic regions implicated in autoimmune disease GWAS. This study was performed by the IMSGC and involved 14,802 cases and 26,703 controls; there was no overlap of samples between these two studies. The Immunochip study was a focused follow-up effort which did not consider all parts of the genome, so some regions were more densely covered than others compared to the 2011 GWAS study. The Immunochip study generated data from 161,311 autosomal markers and identified 48 novel associations. Neither of the MS genetics studies considered the sex chromosomes and we were therefore unable to include sex-linked CSPG genes in this analysis.

Using our knowledge of CSPG biology, we identified a list of 154 autosomal genes (Table 1) involved intimately or remotely in the production and degradation of CSPGs. This includes proteoglycans (Vcan, Acan, Necn, Bcan, Bgn, Bsg, Gpc1-6), degradation enzymes (Adam, Adams, Mmp), and synthesis-related genes (B3gal1-3, B4gal7, Chpf, Chpf2, Chst1-15, Chsy1, Chsy3, Csgalnact1-2, Ext1-2, Ext1l-3, Fam20b), among others.

Animals

All experiments were performed in accordance with the ethical guidelines of the Animal Care Committee at the
| Gene     | Description                                                                 |
|----------|-----------------------------------------------------------------------------|
| Acan     | Aggrecan                                                                    |
| Aco1     | Aconitase 1, soluble                                                        |
| Adam2    | ADAM metalloproteinase domain 2                                              |
| Adam7    | ADAM metalloproteinase domain 7                                              |
| Adam8    | ADAM metalloproteinase domain 8                                              |
| Adam9    | ADAM metalloproteinase domain 9                                              |
| Adam10   | ADAM metalloproteinase domain 10                                             |
| Adam11   | ADAM metalloproteinase domain 11                                             |
| Adam12   | ADAM metalloproteinase domain 12                                             |
| Adam15   | ADAM metalloproteinase domain 15                                             |
| Adam17   | ADAM metalloproteinase domain 17                                             |
| Adam18   | ADAM metalloproteinase domain 18                                             |
| Adam19   | ADAM metalloproteinase domain 19                                             |
| Adam20   | ADAM metalloproteinase domain 20                                             |
| Adam21   | ADAM metalloproteinase domain 21                                             |
| Adam22   | ADAM metalloproteinase domain 22                                             |
| Adam23   | ADAM metalloproteinase domain 23                                             |
| Adam28   | ADAM metalloproteinase domain 28                                             |
| Adam29   | ADAM metalloproteinase domain 29                                             |
| Adam30   | ADAM metalloproteinase domain 30                                             |
| Adam32   | ADAM metalloproteinase domain 32                                             |
| Adam33   | ADAM metalloproteinase domain 33                                             |
| Adamts1  | ADAM metalloproteinase with thrombospondin type 1 motif, 1                  |
| Adamts2  | ADAM metalloproteinase with thrombospondin type 1 motif, 2                  |
| Adamts3  | ADAM metalloproteinase with thrombospondin type 1 motif, 3                  |
| Adamts4  | ADAM metalloproteinase with thrombospondin type 1 motif, 4                  |
| Adamts5  | ADAM metalloproteinase with thrombospondin type 1 motif, 5                  |
| Adamts6  | ADAM metalloproteinase with thrombospondin type 1 motif, 6                  |
| Adamts7  | ADAM metalloproteinase with thrombospondin type 1 motif, 7                  |
| Adamts8  | ADAM metalloproteinase with thrombospondin type 1 motif, 8                  |
| Adamts9  | ADAM metalloproteinase with thrombospondin type 1 motif, 9                  |
| Adamts10 | ADAM metalloproteinase with thrombospondin type 1 motif, 10                 |
| Adamts12 | ADAM metalloproteinase with thrombospondin type 1 motif, 12                 |
| Adamts14 | ADAM metalloproteinase with thrombospondin type 1 motif, 14                 |
| Adamts15 | ADAM metalloproteinase with thrombospondin type 1 motif, 15                 |
| Adamts16 | ADAM metalloproteinase with thrombospondin type 1 motif, 16                 |
| Adamts17 | ADAM metalloproteinase with thrombospondin type 1 motif, 17                 |
| Adamts18 | ADAM metalloproteinase with thrombospondin type 1 motif, 18                 |
| Adamts19 | ADAM metalloproteinase with thrombospondin type 1 motif, 19                 |
| Adamts20 | ADAM metalloproteinase with thrombospondin type 1 motif, 20                 |
| App      | Amyloid beta (A4) precursor protein                                          |
| B3galt6  | UDP-GalbetaGal beta 1,3-galactosyltransferase polypeptide 6                 |
| B3gat1   | Beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P)                |
| B3gat2   | Beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S)                |
| Gene   | Description                                                                 |
|--------|------------------------------------------------------------------------------|
| B3gat3 | Beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I)                 |
| B4galt7| Xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7                 |
| Bcan   | Brevican                                                                     |
| Bgn    | Biglycan                                                                     |
| Bsg    | Basigin                                                                      |
| Chpf   | Chondroitin polymerizing factor                                              |
| Chpt2  | Chondroitin polymerizing factor 2                                             |
| Chst1  | Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1                      |
| Chst2  | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 2                  |
| Chst3  | Carbohydrate (chondroitin 6) sulfotransferase 3                              |
| Chst4  | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 4                  |
| Chst5  | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 5                  |
| Chst6  | Carbohydrate (N-acetylgalactosamine 6-O) sulfotransferase 6                  |
| Chst7  | Carbohydrate (N-acetylgalactosamine 4-O) sulfotransferase 7                  |
| Chst8  | Carbohydrate (N-acetylgalactosamine 4-O) sulfotransferase 8                  |
| Chst9  | Carbohydrate (N-acetylgalactosamine 4-O) sulfotransferase 9                  |
| Chst10 | Carbohydrate sulfotransferase 10                                             |
| Chst11 | Carbohydrate (chondroitin 4) sulfotransferase 11                             |
| Chst12 | Carbohydrate (chondroitin 4) sulfotransferase 12                             |
| Chst13 | Carbohydrate (chondroitin 4) sulfotransferase 13                             |
| Chst14 | Carbohydrate (N-acetylgalactosamine 4-O) sulfotransferase 14                 |
| Chst15 | Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15       |
| Chsy1  | Chondroitin sulfate synthase 1                                               |
| Chsy3  | Chondroitin sulfate synthase 3                                               |
| Cp     | Ceruloplasmin (ferroxidase)                                                  |
| Csgalnact1 | Chondroitin sulfate N-acetylgalactosaminyltransferase 1                   |
| Csgalnact2 | Chondroitin sulfate N-acetylgalactosaminyltransferase 2                 |
| Dse    | Dermatan sulfate epimerase                                                   |
| Ext1   | Exostosin glycosyltransferase 1                                              |
| Ext2   | Exostosin glycosyltransferase 2                                              |
| ExtL1  | Exostosin-like glycosyltransferase 1                                         |
| ExtL2  | Exostosin-like glycosyltransferase 2                                         |
| ExtL3  | Exostosin-like glycosyltransferase 3                                         |
| Fam20b | Family with sequence similarity 20, member B                                |
| Fdx1   | Ferredoxin 1                                                                 |
| Fth1   | Ferritin, heavy polypeptide 1                                                |
| Ftl    | Ferritin, light polypeptide                                                  |
|Fmtm   | Ferritin mitochondrial                                                       |
| Galns  | Galactosamine (N-acetyl)-6-sulfate sulfatase                                 |
| Gpc1   | Glypican 1                                                                   |
| Gpc2   | Glypican 2                                                                   |
| Gpc3   | Glypican 3                                                                   |
| Gpc4   | Glypican 4                                                                   |
| Gpc5   | Glypican 5                                                                   |
Table 1  Names and description of genes associated with CSPG synthesis and turnover (Continued)

| Gene  | Description                                      |
|-------|--------------------------------------------------|
| Gpc6  | Glypican 6                                       |
| Gsta1 | Glutathione S-transferase alpha 1                |
| Gsta2 | Glutathione S-transferase alpha 2                |
| Gsta3 | Glutathione S-transferase alpha 3                |
| Gsta4 | Glutathione S-transferase alpha 4                |
| Gsta5 | Glutathione S-transferase alpha 5                |
| Gstk1 | Glutathione S-transferase kappa 1                |
| Gstm1 | Glutathione S-transferase mu 1                   |
| Gstm2 | Glutathione S-transferase mu 2 (muscle)          |
| Gstm3 | Glutathione S-transferase mu 3 (brain)           |
| Gstm4 | Glutathione S-transferase mu 4                   |
| Gstm5 | Glutathione S-transferase mu 5                   |
| Gstp1 | Glutathione S-transferase pi 1                   |
| Gstt1 | Glutathione S-transferase theta 1                |
| Gstt2 | Glutathione S-transferase theta 2                |
| Hamp  | Hepcidin antimicrobial peptide                   |
| Hapln1| Hyaluronan and proteoglycan link protein 1       |
| Hapln2| Hyaluronan and proteoglycan link protein 2       |
| Has1  | Hyaluronan synthase 1                           |
| Has2  | Hyaluronan synthase 2                           |
| Has3  | Hyaluronan synthase 3                           |
| Heph  | Hephaestin                                       |
| Hmax1 | Heme oxygenase (decycling) 1                     |
| Hmax2 | Heme oxygenase (decycling) 2                     |
| Hp    | Haptoglobin                                      |
| Hpr   | Haptoglobin-related protein                      |
| Ifl3  | Interleukin enhancer binding factor 3, 90 kDa    |
| Ireb2 | Iron-responsive element binding protein 2        |
| Ltf   | Lactotransferrin                                 |
| Mfi2  | Antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 |
| Mgst1 | Microsomal glutathione S-transferase 1           |
| Mgst2 | Microsomal glutathione S-transferase 2           |
| Mgst3 | Microsomal glutathione S-transferase 3           |
| Mmp1  | Matrix metallopeptidase 1 (interstitial collagenase) |
| Mmp2  | Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) |
| Mmp3  | Matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
| Mmp7  | Matrix metallopeptidase 7 (matrilysin, uterine)  |
| Mmp8  | Matrix metallopeptidase 8 (neutrophil collagenase) |
| Mmp9  | Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) |
| Mmp10 | Matrix metallopeptidase 10 (stromelysin 2)       |
| Mmp11 | Matrix metallopeptidase 11 (stromelysin 3)       |
| Mmp12 | Matrix metallopeptidase 12 (macrophage elastase) |
| Mmp13 | Matrix metallopeptidase 13 (collagenase 3)       |
| Mmp14 | Matrix metallopeptidase 14 (membrane-inserted)   |
University of Calgary. Female wild-type C57Bl/6 mice aged 6 to 8 weeks were purchased from Charles River (Montreal) and Extl2−/− mice were previously described [28, 32] and bred at the University of Calgary Animal Health Unit. Experiments conducted with C57Bl/6 wild-type mice from our in-house bred colony or purchased from Charles River did not differ in responses when directly compared. The Extl2-null mice were generated by truncating exon 3 and removal of exon 4 of the Extl2 gene [32]. No defects in breeding or physical impairments were published for the Extl2−/− mice, and we did not observe any obvious abnormalities including weight changes in our colony transferred from Japan through co-author Hiroshi Kitagawa. All experiments were completed on female mice aged 8 to 12 weeks.

**Lysolecithin-induced demyelination**

Experimental demyelination was produced in the ventral spinal cord by stereotactic injection of the toxin lysolecithin [29]. A 10 μL glass Hamilton syringe with a 34-gauge needle was preloaded with a 1% solution of lysolecithin. Animals were anesthetized with a mixture of ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively) administered through an intraperitoneal injection. The analgesic buprenorphine (0.05 mg/kg) was injected subcutaneously prior to surgery. Ophthalmic lubricant was applied to the eyes to prevent them from drying during surgery. A small area on the back was shaved with a razor and the surgical field was disinfected with 70% ethanol and iodine solution. A midline incision was made, and underlying muscle and adipose tissue separated using retractors. Connective tissue between the T3 and T4 vertebra was cut to reveal the spinal cord. The dura mater was opened using a 30-gauge needle. The tip of the Hamilton 34-gauge needle was placed at the surface of the spinal cord, lateral to midline. A baseline measurement was made, and 1.3 mm was subtracted from the baseline measurement to obtain the final

---

**Table 1** Names and description of genes associated with CSPG synthesis and turnover (Continued)

| Gene    | Description                                                                 |
|---------|-----------------------------------------------------------------------------|
| *Mmp15* | Matrix metalloproteinase 15 (membrane-inserted)                             |
| *Mmp16* | Matrix metalloproteinase 16 (membrane-inserted)                             |
| *Mmp17* | Matrix metalloproteinase 17 (membrane-inserted)                             |
| *Mmp19* | Matrix metalloproteinase 19                                                 |
| *Mmp20* | Matrix metalloproteinase 20                                                 |
| *Mmp21* | Matrix metalloproteinase 21                                                 |
| *Mmp23b*| Matrix metalloproteinase 23b                                                |
| *Mmp24* | Matrix metalloproteinase 24 (membrane-inserted)                             |
| *Mmp25* | Matrix metalloproteinase 25                                                 |
| *Mmp26* | Matrix metalloproteinase 26                                                 |
| *Mmp27* | Matrix metalloproteinase 27                                                 |
| *Mmp28* | Matrix metalloproteinase 28                                                 |
| *Ncan*  | Neurocan                                                                    |
| *Ndsl*  | N-deacetylase/N-sulfotransferase (heparan-glucosaminyl) 1                   |
| *Ndsl2* | N-deacetylase/N-sulfotransferase (heparan-glucosaminyl) 2                   |
| *Slc11a1*| Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 |
| *Slc11a2*| Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 |
| *Slc39a14*| Solute carrier family 39 (zinc transporter), member 14                        |
| *Slc40a1*| Solute carrier family 40 (iron-regulated transporter), member 1             |
| *Tf*    | Transferrin                                                                 |
| *Tfrc*  | Transferrin receptor                                                         |
| *Timp3* | TIMP metalloproteinase inhibitor 3                                          |
| *Ust*   | Uronyl-2-sulfotransferase                                                   |
| *Vcan*  | Versican                                                                    |
| *Xylt1* | Xylotransferase I                                                           |
| *Xylt2* | Xylotransferase II                                                          |
described in previous publications (e.g., [21]).

immunofluorescent staining. This selection of tissue cyanine staining. The adjacent sections were taken for elucidation as the section in a given mouse containing vent evaporation. One section per spinal cord was chosen for staining and analysis. Sections were selected tissue sections was done in a humidity chamber to pre-thick sections and mounted on glass slides. Staining of (PDGFR\textsubscript{\alpha}, R&D Systems, AF1062, 1:100), adenomatous polyposis coli (APC, Millipore, clone CC-1, OP80, 1:100), neurofilament heavy chain 200 kD (NF-200, EnCor, RP5A-NF-H, 1:1000), ionized calcium-binding molecule 1 (Iba1, Wako, 019-19741, 1:1000), CD16/32 (Bio-Rad, MCA1075, 1:200), and CD206 (R&D Systems, AF2535, 1:200). Primary antibodies were left on sections overnight at room temperature. Secondary antibodies were diluted in the same dilution buffer as primary antibodies and left for 2 h at room temperature. Slides were mounted with Fluoro-mount G\textsuperscript{+} (SouthernBiotech). Fluorescence imaging was done using the Leica TCS SP8 confocal laser scanning microscope.

Versican exists as 4 isoforms: V0, V1, V2, and V3. The antibody to versican V1 (rabbit anti-mouse versican V0/ V1, Millipore, AB1033) recognizes the GAG beta domain, and the versican V2 antibody (rabbit anti-mouse versican V0/V2, Millipore, AB1032) recognizes the GAG alpha domain, both of which are present in the versican V0 splice isoform. However, due to the lack of colocalization of versican V1/V0 and versican V2/V0 in similar regions (data not shown), we attributed the staining of versican V1 to primarily V1 isoform, although this is displayed in figures as V0/V1.

**Tissue harvesting and processing**

Animals were sacrificed at 7, 14, and 21 days post-injection of lysolecithin. Mice were given a lethal dose of ketamine/xylose anesthetic. Animals were perfused through the left ventricle of the heart with 15 mL of phosphate-buffered saline (PBS) and 15 mL of 4% paraformaldehyde (PFA). The cervical and upper thoracic section of the spinal cord was harvested. Spinal cords were laid on strips of thick card stock to maintain structural integrity. For western blot, spinal cords were immediately flash frozen in liquid nitrogen and stored at – 80 °C until use. For immunohistochemistry, spinal cords were post-fixed overnight in 4% PFA at 4 °C, then transferred into 30% sucrose solution for 72 h. Spinal cords were then frozen into O.C.T. blocks using dry ice and blocks were stored at – 20 °C until sectioning on the cryostat.

**Immunohistochemistry**

Spinal cords frozen in OCT blocks were cut into 20 μm-thick sections and mounted on glass slides. Staining of tissue sections was done in a humidity chamber to prevent evaporation. One section per spinal cord was chosen for staining and analysis. Sections were selected based on proximity to the lesion epicenter; the latter was elucidated as the section in a given mouse containing the largest lesion as determined using eriochrome cyanine staining. The adjacent sections were taken for immunofluorescent staining. This selection of tissue sections is similar to our analyses of other features described in previous publications (e.g., [21]).

All washes were completed using PBS containing 0.25% Tween-20. Blocking of tissue sections was done using horse serum blocking solution (0.01 M PBS, 10% horse serum, 1% bovine serum albumin (BSA), 0.1% cold fish skin gelatin, 0.1% Triton-X100, and 0.05% Tween-20) for 2 h at room temperature. Blocking solution was removed prior to application of primary antibodies. Primary antibodies were diluted in 0.01 M PBS containing 1% BSA, 0.1% cold fish skin gelatin, and 0.5% Triton-X100. Primary antibodies were obtained from various sources and used at dilutions detailed as follows: versican V0/V1 (Millipore, ab1033, 1:200), myelin basic protein (MBP, Abcam, ab7349, 1:1000), Olig2 (Millipore, AB9610, 1:200), platelet-derived growth factor receptor \(\alpha\) (PDGFR\(\alpha\), R&D Systems, AF1062, 1:100), adenomatous polyposis coli
were collected in 50 mL tubes and centrifuged at 1200 rpm for 10 min, then resuspended in same media, except lacking L929 conditioned media. Cells were replated at a density of 50,000 cells/100 μL/well in a 96-well plate. Plates were incubated at 37 °C in 5% CO2. A media switch to serum-free DMEM with supplements was performed at 24 h post-plating, and treatments were added to wells in 1% FBS in DMEM.

Enzyme-linked immunosorbent assay
Supernatant from BMDM cultures (as described above) was harvested at 24 h following the initiation of stimulation. Supernatant was frozen at − 80 °C until use. Samples were thawed to room temperature and ELISA was performed according to manufacturer instructions (Invitrogen).

Mouse MMP 5-plex Luminex assay
BMDM supernatant was harvested at 24 h following the initiation of stimulation. Supernatant was frozen at − 80 °C until the assay was performed. Tubes were stored on ice until used. Samples were processed by Eve Technologies (Calgary) for a panel of 5 MMP members.

Oligodendrocyte precursor cell isolation and harvest
P0–2 CD-1 mouse pups were sacrificed, and brains were isolated. Under a dissection microscope, meninges and choroid plexus tissue were removed from the cortical and ventricular surfaces, respectively. Cortices were dissected away from the hippocampus and cerebellum and cut into 2–3 mm² pieces. A cocktail of papain, DNase, and L-cysteine was used for tissue digestion. The digestion cocktail was added to tissue in a 50-mL tube and the tube was placed in a 37 °C water bath for 30 min, with occasional inversion. More DNase was added if tissue became gel-like. Cells were centrifuged at 1200 rpm for 10 min and resuspended in growth medium. Dissociated cells were plated in T-75 culture flasks pre-coated with poly-L-lysine (10 μg/mL, Sigma). The mixed glial culture was maintained in DMEM containing 10% FBS, 1% GlutaMAX™, 1% sodium pyruvate, and 1% penicillin-streptomycin. Flasks were kept at 37 °C, 8.5% CO2 for 9 days. Half media changes were performed every 3 days. On day 9, flasks were shaken overnight in a 37 °C, 5% CO2 incubator at 220 rpm to dislodge OPCs and microglia from astrocytes. The supernatant containing OPCs and microglia was plated on plastic, uncoated 100 mm dishes for 30 min to allow microglia to adhere. Media containing enriched OPCs was harvested and plated in oligodendrocyte differentiating media (described below) at 5000–10,000 cells/100 μL/well in a 96-well plate pre-coated with poly-L-lysine and other extracellular matrix molecules when appropriate.

Oligodendrocyte differentiating medium was DMEM containing 2% (v/v) B27 supplement (Gibco), 1% (v/v) oligodendrocyte supplement cocktail (see below), 1% (v/v) GlutaMAX™ (Gibco), 100 μM sodium pyruvate (Gibco), 1% (v/v) penicillin-streptomycin (Gibco), 50 μg/mL holo-transferrin (Sigma), 5 μg/mL N-acetyl-L-cysteine (Sigma), 50 ng/mL ciliary neurotrophic factor (PeProTech), and 0.005% (v/v) Trace Elements B (Corning).

Oligodendrocyte supplement cocktail was made from 100 mL DMEM with 1% BSA, 0.06% progesterone (Sigma), 16.1% putrescine (Sigma), 0.005% sodium selenite (Sigma), 0.4% 3,3′,5-triiodo-L-thyronine (Sigma).

Neuron culture and harvest
E16-18 C57Bl/6 pups were obtained from pregnant C57Bl/6 mice purchased from Charles River. The pregnant mouse was anesthetized with a mixture of ketamine and xylazine and the uterine horns were dissected. Pups were sacrificed by decapitation and brains were isolated. Meninges were microdissected from the brain and cortices were cut into small pieces and collected. For tissue digestion, harvested brain tissue was suspended in HBSS (Gibco) containing 0.025% trypsin. The suspension was immersed in a 37 °C water bath with a stir bar to homogenize tissue. Following digestion, heat inactivated FBS was added to inactivate trypsin and cells were filtered into a 50 mL tube and centrifuged at 1200 rpm for 10 min. The supernatant was discarded, and cells were then washed one time with HBSS and centrifuged as before. The supernatant was discarded, and cells were resuspended in growth medium comprised of Neurobasal Plus Medium (Gibco) containing 2% B27 Plus supplement (Gibco). Cells were seeded at 1 to 2 × 10⁵ cells per T-25 flask coated with poly-L-ornithine. Cells were grown in a 37 °C incubator in 5% CO2 for at least 24 h in the T-25 flask before they were harvested using 0.025% trypsin. Cells were then plated at a density of 100,000 cells/well in a 96-well plate coated with poly-L-ornithine in the previously described growth medium. Neurons were allowed to grow for 24 h prior to treatment with BMDM conditioned media.

Cell staining and imaging
All washing was done using PBS. Plates were placed on an orbital shaker during all incubations. For OPCs, blocking was done using 10% normal goat serum (NGS) in PBS or Odyssey® Blocking Buffer (Licit) for 1 h at room temperature. Primary antibody against O4 (Millipore) was diluted 1:50 in blocking buffer and incubated for 2 h at room temperature or overnight at 4 °C. An anti-mouse IgM antibody conjugated to Alexa Fluor® 488 (Jackson ImmunoResearch) as well as nuclear yellow was added in blocking buffer for 1 h at room temperature. Plates were washed with PBS and imaged using the ImageXpress Micro XLS Widefield High-Content Analysis System (Molecular Devices).
For BMDMs, for detection of intracellular molecules, cells were permeabilized using 0.025% Triton-X100 for 5 min at room temperature. No permeabilization was required for surface molecules. Blocking was done using Odyssey® Blocking Buffer (Licor) for 30 min at room temperature. Primary antibodies were diluted in the same blocking buffer incubated overnight at 4 °C. Secondary antibodies were diluted in the same blocking buffer and incubated for 1 h at room temperature. Nuclear yellow was added in PBS and incubated for 10 min. Plates were washed with PBS and imaged using the ImageXpress Micro XLS Widefield High-Content Analysis System.

Image analysis
For immunohistochemistry, images were processed and analyzed using ImageJ. All images were blinded prior to analysis. For percent of lesion area analyses, lesion area was demarcated using MBP staining. A disruption in MBP density was determined to be lesional. The lesion area was isolated and area of signal of interest was determined using differential thresholding. The area occupied by the signal was normalized to total area of the lesion or represented as an absolute area. For axonal counts in the lesion, the lesion area was demarcated using MBP. Differential thresholding was used to isolate individual axons present inside the lesional area and was automatically counted. The number of axons within the lesion was normalized to total lesion area to obtain density. For oligodendrocyte-lineage cell counting and scoring, the same approach to demarcating the lesion area was used. Images containing Olig2+ nuclei were overlaid with either PDGFRα staining or CC1 staining. Colocalization of either PDGFRα or CC1 with Olig2 was determined to be an OPC or mature oligodendrocyte, respectively. The density of oligodendrocytes in the lesions was calculated by isolating the lesion area and counting the number of Olig2+ nuclei and normalizing counts to the respective lesion area. Percentage of OPCs or mature oligodendrocytes was calculated using the total number of Olig2+ nuclei. We assessed the mean fluorescence intensity of the macrophage activation markers CD16/32 and CD206 within the lesion, internally normalized to the background fluorescence. Mean fluorescence intensity was assessed within the area of positive immunoreactivity. For immunocytochemistry, images were analyzed on the MetaXpress High-Content Image Acquisition and Analysis Software (Molecular Devices, San Jose, CA). Appropriate thresholds were determined for true signals. OPC cultures were analyzed using the Neurite Outgrowth program, and BMDM cultures were analyzed using the Cell Scoring program. Both processing protocols are from Molecular Devices.

Statistical analysis
All statistical analysis was performed with GraphPad Prism 8.0. Student’s t test, ordinary one-way ANOVA, and two-way ANOVA statistical tests were used with an alpha of 0.05. Individual tests and post hoc tests are described in figure legends. For assessment of lesions with respect to versican V1 deposition, oligodendrocytes, lesion area, macrophage/microglia, and axons, between 4 and 12 individual animals were used, and one section per lesion was quantified. The individual performing the surgery was not blinded to the genotype of animals; however, images were blinded prior to analysis on the ImageJ software. Each animal/lesion was considered an n of 1. In some cases, the quality of the tissue section or the staining was not deemed adequate for blinded analysis, and these were omitted. For lesion area analysis using MBP staining, animals from two sets of surgeries were combined. Other immunohistological analyses were performed on one of the two sets of surgeries.

BMDMs were derived from 1 to 2 wild-type or ETL2−/− mice. OPCs were derived from between 8 to 12 CD-1 pups. Neurons were derived from 8 to 12 C57BL/6 prenatal pups aged E13-15. For all cell culture experiments, each data point was derived from one well. Subsequent replicates of experiments were performed and reported in figure captions.

Results
SNP data mining from MS databases implicates ETL2
Ignoring pseudogenes, we identified 154 autosomal genes involved in the metabolism of CSPGs (Table 1). Several of these genes map close to each other so after allowing a 100-kb extension from both ends, the 154 genes were found to map to 125 distinct genomic regions containing 7382 SNPs in the GWAS (median 42 SNPs per region, range 7–291) and 3139 SNPs (from 118 of the 125 regions) in the Immunochip (median 5 SNPs per region, range 1–494).

Both the GWAS and the Immunochip studies included secondary analyses of disease severity, as measured by the Multiple Sclerosis Severity Score and the clinical course (relapse onset vs progressive onset). None of these secondary analyses identified significant associations so it was unsurprising that no enrichment for association was seen among the SNPs mapping close to CSPG-related genes.

Six of the SNPs from the GWAS showed genome-wide significant evidence for association with all of these SNPs mapping to the region containing ETL2. These SNPs all showed concordant effects on risk in the Immunochip study with significant but less extreme p values (ranging from 1.4e−4 to 3.7e−6). All six of the SNPs mapping to the region containing the ETL2 gene were confirmed as associated with genome-wide
significance in the larger MS GWAS meta-analysis (IMSGC 2017 BioRxiv 143933) that involved a total of 14,802 cases and 26,703 controls, including those considered in the 2011 GWAS. Combining all available genetic data showed that there are likely at least two independent MS susceptibility variants in the region of the EXTL2 gene (IMSGC 2017 BioRxiv 143933); 5 (rs12746227, rs11809572, rs11581062, rs11588568, and rs7541397) of the 6 SNPs were identified tag one of these effects and the remaining SNP (rs7552544) tags the second. In the final combined analysis, there was highly significant evidence for association with MS in this region ($p = 1.1e^{-22}$). These data thus confirm any reasonable doubt that genetic variation in this region influences susceptibility to MS; however, it is important to note that EXTL2 is not the only gene in the region of these associated SNPs. It is therefore not possible to conclude with certainty that these variants exert their effects on risk via EXTL2 rather some other gene within the region. Nonetheless, the genetic analyses provided a solid rationale to evaluate the biology of EXTL2 in models of MS.

**Increased deposition and persistence of versican V1 and CS-A glycosaminoglycan following injury in the EXTL2$^{-/-}$ spinal cord**

Based on previous literature suggesting that EXTL2 is a negative regulator of CSPG synthesis [32], we first asked whether loss of EXTL2 results in increased CSPG deposition into an injured area during the reparative and remyelinating phases. We induced lysolecithin lesions in the ventral columns of spinal cords of wild-type and EXTL2$^{-/-}$ animals and evaluated total CS-A (not shown) and versican V1 deposition into the lesion at 14 and 21 days post-lesion (dpl). Versican V1 was focused upon since this was the predominant lectican CSPG member produced after lysolecithin injury [21].

Eriochrome cyanine staining shows a demarcated area in the ventral column of the spinal cord with distinctive loss of myelin in the lesion, corresponding to an increase in V1 immunoreactivity (Fig. 1a, b). In both wild-type and EXTL2$^{-/-}$ spinal cords, upregulation of V1 was limited to the lesion site (Fig. 1c). By 14 dpl, there was a greater accumulation of V1 in EXTL2$^{-/-}$ lesions compared to wild-type (Fig. 1d, e). At day 21, V1 was largely cleared from the wild-type lesion, whereas it remained in the lesion of EXTL2$^{-/-}$ animals (Fig. 1d, f).

**EXTL2$^{-/-}$ mice exhibit no overt differences in OPC repopulation and maturation following injury**

We next asked whether the extensive deposition and persistence of CSPGs in the EXTL2$^{-/-}$ animals impacted the remyelination process. As there is extensive literature on the inhibitory nature of CSPGs on OPGs, we expected a deficiency or delay in remyelination in the EXTL2$^{-/-}$ mice. In the spinal cord lysolecithin model, OPCs loss occurs in the acute phase of injury and they then repopulate the lesion after 3–4 days, with subsequent accumulation of OPCs and eventual differentiation into mature oligodendrocytes and remyelination ([29]; Jensen et al., 2018). We analyzed spinal cord sections stained for the transcription factor Olig2 that defines cells of the oligodendrocyte lineage, the surface receptor PDGFRα that is selective to OPCs, and APC (adenomatous polyposis coli, also called CC1, labeling mature oligodendrocytes) to determine the number of oligodendrocyte-lineage cells present within the lesion at days 14 and 21 post-injury (Fig. 2a, e). Unexpectedly, we found no significant differences in the density of Olig2$^+$ oligodendrocyte-lineage cells within the lesion (Fig. 2b, f), or in proportions of Olig2$^+$PDGFRα$^+$ OPCs (Fig. 2c, g) and Olig2$^+$APC$^+$ oligodendrocytes (Fig. 2d, h) at any of the assessed time points. No deficiencies in OPC recruitment to the lesion, nor maturation into oligodendrocytes, was apparent by day 14 and day 21 after lysolecithin injury.

**Exacerbated lesion area and decreased axonal density in EXTL2$^{-/-}$ lesions**

In our characterization of the EXTL2$^{-/-}$ phenotype following injury, we found an exacerbated injury area demarcated by loss of MBP immunoreactivity (Fig. 3a). Analysis of the total area of MBP disruption in both wild-type and EXTL2$^{-/-}$ lesioned spinal cords showed a larger area of demyelination in EXTL2$^{-/-}$ spinal cords at day 14 (Fig. 3b) and a similar but non-statistically significant trend at day 21 (Fig. 3c) following injection of lysolecithin compared to those of wild-type animals. We then hypothesized that there could be a corresponding loss of axons in the demyelinated area. To identify axons, we used an antibody against the 200 kD neurofilament (NF200), which reliably labels axons in the ventral column (Fig. 3d). Qualitatively, there was close correlation between the area of axonal loss to area of demyelination (Fig. 3d). At day 14, we observed a decreased axonal density in the EXTL2$^{-/-}$ lesions, corroborating our finding of a larger area of demyelination (Fig. 3e, f). Lesions from day 21 animals had too much background to be evaluated for axons. Overall, we observed a larger lesion and a greater loss of axons in the EXTL2$^{-/-}$ spinal cord with injection of lysolecithin.

**Increased accumulation of microglia and macrophages within lesions of EXTL2$^{-/-}$ animals**

Given our previous report of CSPGs being a stimulator of macrophages in EAE [18] and our previous finding of exacerbated injury in the EXTL2$^{-/-}$ spinal cord, we investigated whether there were corresponding pro-
inflammatory phenotypes in lesional microglia/macrophages in EXTL2−/− animals. Macrophages and microglia were labeled by Iba1 (ionized calcium-binding adaptor molecule 1) (Fig. 4a). We determined that there was a greater area of lesion covered by Iba1 immunoreactivity at day 14 (Fig. 4b), indicating an increase in macrophages/microglia density within the lesion, in the EXTL2−/− animals. Greater Iba1 immunoreactivity was still observed at day 21 (Fig. 4c), suggesting macrophages/microglia persisted for longer in the EXTL2−/− lesions.

No difference in the surface marker expression of CD16/32 and CD206 in lesional Iba1+ cells in wild-type and EXTL2−/− mice

To further resolve whether differences in polarization exist in the Iba1+ cells in the wild-type and EXTL2−/− lesions, we probed tissue sections using immunofluorescence staining for M1-like pro-inflammatory and M2-like anti-inflammatory surface markers, CD16/32 and CD206 [33], respectively (Fig. 5a, d); the pro-inflammatory enzyme inducible nitric oxide synthase (iNOS) was attempted but did not result in reliable staining. For both CD16/32 and CD206, intensity was not significantly different between wild-type and EXTL2−/− lesions (Fig. 5b, c, e, f), indicating that expression levels of these receptors are similar and that there was no apparent alterations in microglia/macrophage phenotype in EXTL2−/− animals.

Cultured EXTL2−/− BMDMs upregulate iNOS, secrete more TNFα, and differentially regulate MMPs in response to CSPGs

Due to limitations of assessing the activity of Iba1+ cells in the lesion using fixed tissue sections, we cultured murine-derived BMDMs to examine functional or phenotypic
differences between wild-type and EXTL2−/− macrophages upon stimulation. As monocyte-derived macrophages constitute a significant portion of immune cells present in the lyssolecithin-induced lesion (unpublished observations), we reasoned that BMDMs are an appropriate population of cells to study as a model for macrophages in the lesion. We hypothesized that excessive deposition and persistence of CSPGs in EXTL2−/− animals underlies the prolonged

![Figure 2](image-url)

**Fig. 2** Immunostaining and quantification of oligodendrocyte lineage cells following injury. Representative images of lesions labeled with Olig2, PDGFRα, and APC (CC1) are shown in a and e, for days 14 and 21, respectively. Scale bar = 200 μm. Insets are high magnification images of individual Olig2+ nuclei co-labeled with PDGFRα or APC. Density of all Olig2+ nuclei are quantified for day 14 in b and day 21 in f. Proportion of Olig2+PDGFRα+ OPCs at both day 14 and 21, calculated as a fraction of all Olig2+ cells, are shown in c and g. c shows day 14 and g shows day 21 analyses. Graphs show mean with standard deviation. Two-tailed, unpaired Student’s t test
myelin disruption and macrophage/microglia accumulation or activation, which consequently contributes to exacerbated injury. BMDMs were harvested from both wild-type C56Bl/6 and EXTL2−/− mice and stimulated with a commercial CSPG mixture containing versican for 24 h. Basally, wild-type and EXTL2−/− BMDMs were comparable with regard to surface expression of CD45, F4/80, CD11b, and CD68. Both groups of naïve BMDMs also exhibited similarly low expression of CD206, MHC II, and CD11c (data not shown).
Cultured BMDMs were stained for the pro-inflammatory marker iNOS (Fig. 6a), and number of cells with enhanced iNOS expression was quantified. While similar numbers of unstimulated wild-type and EXTl2−/− BMDMs expressed iNOS, CSPG stimulation resulted in a marked increase in iNOS+ EXTl2−/− BMDMs (Fig. 6b).

Multiplex analysis to detect the presence of secreted MMP members was performed on supernatant harvested from stimulated wild-type and EXTl2−/− BMDMs (Fig. 6c–g). We found that EXTl2−/− BMDMs secreted more MMP8 relative to wild-type BMDMs (Fig. 6e). We observed a similar trend in MMP2 secretion; however, this did not reach statistical significance (Fig. 6c). No significant differences in MMP3 secretion were detected in any group (Fig. 6d). Upon stimulation with CSPGs, pro-MMP9 was the only MMP to be significantly increased in the wild-type BMDM conditioned medium (Fig. 6f). Unexpectedly, wild-type BMDMs decreased secretion of MMP12 in response to CSPG stimulation, and EXTl2−/− BMDMs exhibited a baseline decrease in MMP12 production and did not alter MMP12 production with stimulation (Fig. 6g).

Assessment of the BMDM conditioned media using enzyme-linked immunosorbent assay (ELISA) analysis revealed significantly increased amounts of TNFα in the supernatant of EXTl2−/− BMDMs compared to wild-type BMDM supernatant in response to CSPG stimulation (Fig. 6h). To corroborate this in vitro finding, we stained tissue from wild-type and EXTl2−/− animals 14 days post-injury for TNFα (Fig. 6i). We found greater areas of immunoreactivity of TNFα in EXTl2−/− spinal cords than wild-type (Fig. 6j), and pattern of staining appears to correlate closely with CD68, a surface marker highly expressed by microglia/macrophages [34].

**Conditioned media from EXTl2−/− BMDMs do not kill cultured neurons or OPCs**

Given that in the presence of CSPGs, EXTl2−/− BMDMS exhibited a more pro-inflammatory phenotype in culture, we next asked whether the pro-inflammatory nature of these macrophages may underlie the exacerbated lesion size and axonal loss observed in EXTl2−/− animals following lysolecithin injection (Fig. 3). To exclude the possible contribution of contact-mediated cell death, we harvested conditioned media from cultured wild-type and EXTl2−/− BMDMs stimulated with CSPGs. These conditioned media were applied to neurons in a 1:1 ratio with neuron culture media for 24 h. Although some cultures showed attrition of neuronal numbers qualitatively when exposed to the conditioned media of EXTl2−/− BMDM, analyses of pooled results across 3 experiments (quadruplicate cultures each) did not show a quantitative loss of neurons when compared to cultures exposed to conditioned media from wild-type BMDMs (Fig. 7a, b).

Next, conditioned media were applied to primary OPC cultures. Cells were cultured for 24 h before fixing and assessment of process outgrowth using the oligodendrocyte lineage marker O4 (Fig. 7c). EXTl2−/− and wild-type BMDM conditioned media had the same effect on OPC growth (Fig. 7c, d). The conditioned media of both wild-type and EXTl2−/− BMDMs stimulated with CSPGs impaired outgrowth, likely due to the CSPGs...
Three days following the application of BMDM conditioned media to OPCs, cells were assessed for MBP expression as a determinant of viability and maturation. Between wild-type and EXTL2−/− conditions, the total number of cells was highly comparable, and the majority were viable and MBP-expressing (Fig. 7e). Measurement of the mean intensity of MBP staining per cell as well as the mean area of MBP staining per cell did not reveal obvious differences in both intensity (not shown) and area of MBP staining (Fig. 7f) in cultures exposed to conditioned media from wild-type or EXTL2−/− BMDMs.

Finally, the presence of several growth factors normally added to the growth medium of OPC cultures may obscure differences found in the injury milieu in vivo. We therefore conducted the same 24-h OPC experiment as shown in Fig. 7c and d, but without fetal bovine serum and growth factors added to the standard OPC growth medium. In this minimal medium (MM), OPC growth was poor in comparison to standard OPC medium (Fig. 7g, h). OPCs grown in MM were more sensitive to inhibition of process outgrowth when exposed to CSPG-stimulated BMDM conditioned media; however, there were no differences in OPC growth when exposed to wild-type and EXTL2−/− conditioned media (Fig. 7i).

Overall, the OPC results in tissue culture support the in vivo observations that repopulation of lysolecithin lesions by OPCs and oligodendrocytes was not impaired in EXTL2−/− mice. In contrast, using neurons in culture, we were unable to mimic the conditions in vivo whereby an exacerbated axonal loss occurred in EXTL2−/− demyelinated lesions.

Discussion
In the present study, we show that dysregulation of CSPG production following CNS injury profoundly impacts the inflammatory state of a demyelinated lesion. Loss of the enzyme EXTL2, a regulatory mechanism serving to limit CSPG synthesis, resulted in more extensive versican deposition into a lysolecithin-induced demyelinated injury, a larger area of myelin disruption with an associated decrease in axonal density within the lesion, and greater accumulation of macrophages and microglia (schematic shown in Fig. 8). The increased versican load and microglia/macrophage representation within the demyelinated lesion of EXTL2−/− mice may contribute to the expansion of lesion and axonal loss, but we were not able to show in culture that macrophages from EXTL2−/− mice exposed to CSPGs promote neuronal or OPC death. While our results support the increasing recognition that an elevated load of CSPGs can be pro-inflammatory and injurious in vivo, in addition to their known roles in inhibiting axonal...
Fig. 6 Assessment of iNOS expression in cultured BMDMs following CSPG stimulation; MMP 5-plex assay and ELISA analyses of conditioned media from cultured BMDMs. Cultured BMDMs from wild-type and EXTL2<sup>−/−</sup> mice were stained for iNOS and nuclear yellow (NY). Representative images for unstimulated and CSPG-stimulated cells are shown in a. Scale bar = 100 μm. b Comparison of number of iNOS<sup>+</sup> cells between wild-type and EXTL2<sup>−/−</sup> cells, unstimulated or with CSPG stimulation. n = 4 wells per condition. Two-way ANOVA with Sidak’s multiple comparisons test. c-g Fold change of MMP2, MMP8, MMP3, pro-MMP9, and MMP12 detected in conditioned media from both wild-type and EXTL2<sup>−/−</sup> BMDMs, unstimulated and CSPG stimulated, respectively. Ordinary one-way ANOVA with Tukey’s multiple comparisons test. Raw quantities of MMPs in pg/mL ranged from 37.1 to 58.1 for MMP2, 0.1 to 10.3 for MMP3, 305.7 to 490.0 for MMP8, 157.6 to 6265.0 for pro-MMP9, and 3936.5 to 11,558.3 for MMP12. Fold change is calculated over unstimulated cells. h TNFα levels in BMDM conditioned media as determined by ELISA. Two-way ANOVA with Sidak’s multiple comparisons test. i Representative images of TNFα and CD68 staining in day 14 lyssolecithin-injured spinal cord tissue. Scale bar = 200 μm. j Analysis of absolute TNFα immunoreactive area within lesions at day 14 in wild-type and EXTL2<sup>−/−</sup> spinal cords. All graphs are mean with SEM, except for panel j (mean with standard deviation). Two-tailed, unpaired Student’s t test. *p < 0.05, **p < 0.01
regeneration and remyelination, the precise mechanisms by which EXTL2 deficiency promotes injury remain elusive.

Results from genetic studies strongly implicate genes from the region containing the EXTL2 gene but cannot define with precision which of the genes from the region...
is relevant. To date, there are no well-powered studies of MS progression so it is not possible to infer genetically whether EXTL2 (or any other gene) might be involved in the neurodegenerative aspects of the disease. In a small study of 147 patients, Saigoh et al. (2016) analyzed SNPs in the region of the related gene chondroitin sulfate β-1,4-N-acetylgalactosaminyltransferase-1 (ChGn-1), an enzyme also involved in CSPG synthesis, and suggested that the coding SNP (cSNP: rs140161612) might influence progression, particularly in male patients. In short, in the absence of well-powered GWAS for MS progression, it is challenging to assess genetically whether genes that regulate CSPG metabolism might be involved in MS progression.

To our knowledge, this is the first study to explore the role of EXTL2 within the CNS. Several questions remain unanswered. While we observed greater CSPG production and deposition into the lesion, the cellular sources of these CSPGs have yet to be confirmed. Multiple cell types are known to produce CSPG members, including astrocytes, OPCs, and microglia/macrophages. However, for versican V1, its major source is cells of myeloid origin [35]. In previous work, we found that CSPGs in lysolecithin lesions were expressed within Iba1+ microglia/macrophages [22]; versican V1 is the lectican CSPG member elevated within these lesions [21]. Moreover, by in situ hybridization, versican V1 transcript was detected in CD45+ cells (mostly microglia/macrophages) within lesions [18]. Whether expression within the lysolecithin lesions could be contributed by circulating versican is unknown. Another unanswered question is whether the enzymatic activity of EXTL2 is altered in the lysolecithin lesion, as this should provide further insight into the regulation of CSPG synthesis following injury.

Others have shown that inhibition of CSPG signaling through perturbation of the CSPG receptor PTPσ skews the microglia/macrophage response towards an anti-inflammatory “M2-like” state with associated increases in IL-10 [25]. Given that CSPGs, particularly versican, have a known role in the modulation of inflammation [19, 36], whether CSPGs deposited by microglia/macrophages locally can act in an autocrine or paracrine fashion to further promote inflammation while reducing “M2-like” condition is another unanswered question. In our study, we found no difference in the expression of CD16/32 and CD206, presumed “M1-like” and “M2-like,” respectively, in lesional macrophages/microglia (Fig. 5). However, previous work has suggested that a population of mononuclear phagocytes co-expresses the “M1-like” iNOS and the “M2-like” Arginase-1 simultaneously [37]. Thus, the use of only two markers in our study does not adequately reflect differences in macrophage/microglia phenotype, and cannot exclude the possibility that further analysis using a more extensive panel of markers or employing techniques such as RNA sequencing may reveal more subtle changes induced the EXTL2−/− mice.

The Extl2 gene lies close to the Csf-1 gene on chromosome 11q11-12, so there is a possibility of mutating the Csf-1 gene as a result of the Extl2 manipulation. A loss of function mutation in the Csf-1 gene in mice produces
the op/op model for osteopetrosis, which is accompanied by a number of overt manifestations such as a lack of teeth, stunted growth, a domed skull, and distinct re-duction in the number of macrophages across several tissues. Our Extl2−/− animals have similar abundance and distribution of Iba1+ cells in the spinal cord, and do not exhibit the distinctive lack of teeth. As we have not observed these outward presentations, we concluded that deleterious alterations to the Csf-1 gene are unlikely in our Extl2-deficient animals. We attempted to measure CSF-1 production by BMDM from wild-type or Extl2−/− animals but were unsuccessful in detecting its expression using ELISA.

Unexpectedly, we did not find any deficiency in the extent of OPC repopulation of the lesion in the Extl2−/− animals compared to wild-type, in contrast to several lines of evidence supporting the inhibitory nature of CSPGs to remyelination. A recent study by the Yang group provides evidence that the CSPG-PTPσ signaling pathway is a suppressor of OPC migration and maturation. The authors report that perturbation of CSPG signaling (by using the PTPσ inhibitor intracellular sigma peptide) significantly accelerated recovery from dorsally injected lysolecithin and decreased severity of experimental autoimmune encephalomyelitis (EAE) [38]. It is important to note that Extl2 is not specific to versican synthesis, and that versican was the focus of our current work because of its pronounced upregulation following injury in the lesion after lysolecithin demyelination, whereas other lectican CSPG members were not [21]. NG2, a non-lectican member of the CSPG family, is highly expressed by OPCs and upregulated upon injury. There is evidence to suggest that NG2 plays a key role in the injury response of OPCs, where loss of NG2 in OPCs reduces their mitotic index and delays remyelination [39]. Loss of Extl2 in OPCs may similarly affect NG2 expression, thus counter-balancing the inhibitory effects of lesional versican.

Although the formation of the glial scar, largely contributed to by CSPGs, is thought to be protective in limiting the area of injury, we found a significantly greater lesional area in the Extl2−/− mice. Previous work from others has shown that the disruption of CSPG deposition in the acute phase of injury (1–3 dpl) exacerbates injury and impedes remyelination and resolution of inflammation [40]. The time points we selected for our current work do not necessarily reflect the acute injury phase, and future studies may focus on early time points to determine whether disruption of glial scar formation occurs in Extl2−/− mice. However, a report of CSPG members in active MS lesions suggests a less clear role of CSPGs. In chronic active lesions, CSPGs are seen at the borders of the lesion; however, foamy macrophages were present in the lesion core with punctate staining of CSPGs associated with the cells [4]. CSPGs, at an earlier time, may have been present uniformly throughout the lesion and are being degraded and endocytosed by macrophages from the lesion center. This, supported by our previous study in EAE [18], implies that CSPGs may be exacerbating inflammation rather than serving a neuroprotective role.

This study did not address the closely related group of ECM to the CSPGs, the heparan sulfate proteoglycans (HSPGs). Due to the N-acetylglucosaminyltransferase activity of Extl2, it has been proposed that Extl2 also plays a role in HSPG synthesis, where it is thought to be a promoter of HSPG production rather than a regulator. There is some evidence to suggest that knockdown of Extl2 may reduce HSPG synthesis [41, 42]. HSPGs are largely regarded as a growth-permissive ECM member. Whether HSPGs are downregulated as a result of Extl2 knockout was not determined, and consequently, what impact reduced HSPG production may have on inflammation and repair.

Our work and others have shown that approaches to reducing CSPGs may be key in promoting regeneration in the CNS. The bacteria-derived enzyme chondroitinase ABC has previously been used in SCI and white matter ischemia models, where treated animals exhibited histological and functional improvements over untreated animals [14, 24, 27]. Pharmacological agents that reduce biosynthesis of CSPGs have been proposed as an alternative to CSPG-cleaving enzymes [21, 22]. Protamine is a heparan neutralizing drug that was also found to block CSPG-mediated inhibition on OPC growth in culture [43].

Overall, our data supports previous reports that Extl2 is a negative regulator of CSPG biosynthesis. We have shown that the loss of Extl2 results in the excessive production of versican in response to demyelination, which consequently results in protracted response from microglia/macrophages. This study provides the first evidence for a role of Extl2 in regulating the responses to CNS demyelination and identifies a novel target for future studies investigating CSPGs and their role in CNS injury. Our results also set the stage to evaluate the mechanisms by which the CSPG-elevated microenvironment leads to exacerbation of lesion size following demyelination.

**Conclusions**

This study suggests a potential genetic MS risk association with the Extl2 gene, which encodes for Extl2, a negative regulator of CSPG biosynthesis. We conclude from the present study that CSPGs may be a potent modulator of neuroinflammation in the context of a demyelinating injury. Dysregulation of the Extl2 enzyme results in increased accumulation of CSPGs within the white matter injury also associated with a decreased axonal density and exacerbated injury area. We highlight
the accumulation of CSPGs as a promoter of axonal injury, through the potential augmentation of the inflammatory macrophage response. In vitro cell culture results suggest that CSPGs are able to promote an inflammatory response through induction of TNFα secretion, as well as some MMPs. In addition to their better described inhibitory roles for remyelination and axonal repair in the CNS, these results indicate that CSPGs are also promoters of detrimental neuroinflammation in white matter demyelination.

Abbreviations
BMDM: Bone marrow-derived macrophages; ChABC: Chondroitinase ABC; CSPGs: Chondroitin sulfate proteoglycans; ECM: Extracellular matrix; EXTL2: Exostosin-like 2; HSPGs: Heparan sulfate proteoglycans; MBP: Myelin basic protein; MMPs: Matrix metalloproteinases; NF200: 200 kDa neurofilament; OPC: Oligodendrocyte precursor cell; PBS: Phosphate-buffered saline; PFA: Paraformaldehyde; SNP: Single nucleotide polymorphism; TNF-α: Tumor necrosis factor α

Acknowledgements
VWY acknowledges Canada Research Chair (Tier 1) support.

Authors’ contributions
AP contributed to the design of this work, generated, and analyzed all of the in vivo mouse data, as well as the majority of cell culture data. MM, YF, and SG contributed to generating cell culture data. KSR contributed to the interpretation of data. CS contributed to the provision and maintenance of reagents. HK provided the EXTL2 interpretation of data. CS contributed to the provision and maintenance of reagents. SG contributed to generating cell culture data. KSR contributed to the design of this work, generated, and analyzed all of the

Funding
This study was supported by operating grants from the Canadian Institutes of Health Sciences, the AIHS Alberta/Novartis Translational Research Fund, and the Multiple Sclerosis Society of Canada. YD acknowledges postdoctoral fellowship support from the Alberta MS Collaboration. KSR and ELS are Canada Vanier Scholars and acknowledge additional doctoral support from the Alberta MS Collaboration. VHW conceptualized this work and provided funding and all materials for this study. All authors read and approved the final manuscript.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
All animal experiments were performed with ethics approval from the Animal Care Committee at the University of Calgary, following guidelines of the Canadian Council of Animal Care. There are no human studies in this manuscript.

Consent for publication
All authors have consented to the publication of this manuscript.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, T2N 4 N1, Calgary, Canada. 2Kobe Pharmaceutical University, Kobe, Japan. 3University of Cambridge, Cambridge, UK. 4University of Calgary, 3330 Hospital Drive, Calgary, Alberta T3A 4X9, Canada.

Received: 5 April 2020 Accepted: 13 July 2020
Published online: 23 July 2020

References
1. Bumsire ER, Bradbury EJ, Review: manipulating the extracellular matrix and its role in brain and spinal cord plasticity and repair. Neuropathol Appl Neurobiol. 2014;40:26–59.
2. Pu A, Stephenson EL, Yong VW. The extracellular matrix: focus on oligodendrocyte biology and targeting CSPGs for remyelination therapies. Glia. 2018;66:1809–25.
3. Mohan H, Krumholz M, Sharma R, Eselle S, Junker A, Sot M, Newcombe J, Wekerle H, Hoffield R, Larssmann H, Meinel E. Extracellular matrix in multiple sclerosis lesions: fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol. 2010;20:966–75.
4. Sobel RA, Ahmed AS. White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis. J Neuropathol Exp Neurol. 2001;60:1198–207.
5. Lau LW, Cua R, Krouch MB, Haylock-Jacobs S, Yong VW. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci. 2013;14:722–9.
6. Suttkus A, Rohr SQ, Weigel S, Glöckner P, Arendt T, Morawski M, Aggrecan, link protein and tenascin-R are essential components of the perineuronal net to protect neurons against iron-induced oxidative stress. Cell Death Dis. 2014;5:e1119.
7. Asher RA, Morgenstern DA, Fisher PS, Adcock KH, Oohita A, Braisted JE, Levine JM, Margolis RJ, Rogers JH, Fawcett JW. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J Neurosci. 2000;20:2427–38.
8. Asher RA, Morgenstern DA, Shearer MC, Adcock KH, Pesheva P, Fawcett JW. Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells. J Neurosci. 2002;22:2225–36.
9. Beghelli AT, Dours-Zimmermann MT, Baras FM, Brosius A, Zimmermann DR, Zur AAD. Lesion-induced differential expression and cell association of neurocan, brevican, versican V1 and V2 in the mouse dorsal root entry zone. Neuroscience. 2005;133:749–62.
10. Hallmann R, Zhang X, Di Russo J, Li L, Song J, Hannocks MJ, Sorokin L. The regulation of immune cell trafficking by the extracellular matrix. Curr Opin Cell Biol. 2015;36:54–61.
11. Jones LL, Margolis RJ, Tuuszyński MH. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol. 2003;182:399–411.
12. Jones LL, Yamaguchi Y, Stallcup WB, Tuuszyński MH. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J Neurosci. 2002;22:2792–803.
13. Prospera F, Carulli D, Asher RA, Muir EM, Carnagio LM, Van Kuppevelt TH, Ten Dam GB, Furukawa Y, Mikami T, Sugahara K, Toida T, Geller HM, Fawcett JW. Chondroitin 6-sulphate synthesis is upregulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory gila. Eur J Neurosci. 2005;21:787–803.
14. Deng Y-P, Sun Y, Hu L, Li Z-H, Xu Q-M, Pei Y-L, Huang Z-H, Yang Z-G, Chen C. Chondroitin sulfate proteoglycans impede myelination by oligodendrocytes after perinatal white matter injury. Exp Neurol. 2015;269:213–23.
15. Karimi-Abdolrezaee S, Schutt D, Wang J, Fehlings MG, Zheng JC. Chondroitinase and growth factors enhance activation and oligodendrocyte differentiation of endogenous neural precursor cells after spinal cord injury. PLoS One. 2012;7.
16. Siebert JR, Osterhoff DJ. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J Neurochem. 2011;119:716–88.
17. Wang H, Katagiri Y, McCann TE, Unsworth E, Goldsmith P, Yu Z-X, Tan F, Santiago L, Mills EM, Wang Y, Syms AJ, Geller HM. Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci. 2008;121:3083–91.
18. Stephenson EL, Mishra MK, Moussienko D, Lafamme N, Riest S, Ling C-C, Yong VW. Chondroitin sulfate proteoglycans as novel drivers of leucocyte infiltration in multiple sclerosis. Brain. 2018;141:1094–110.
inflammatory response induced by polyinosine-polyribidylic acid stimulation. J Biol Chem. 2017;292:51–63.

20. Prydz K, Dalen KT. Synthesis and sorting of proteoglycans. J Cell Sci. 2000; 113:193–205.

21. Keough MB, Rogers JA, Zhang P, Jensen SK, Stephenson EL, Chen T, Hurblt MG, Lau LW, Rawj KS, Piemel JR, Koch M, Ling C-C, Yong WW. An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat Commun. 2016;7.

22. Lau LW, Keough MB, Haylock-Jacobis S, Cua R, Döring A, Sloka S, Stirling DP, Rivest S, Yong WW. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol. 2012;2:419–32.

23. Bantit AW, Davies M, Marchand F, Hartley R, Grist J, Yip P, Mcmahon SB, Bradbury EJ. Chondroitinase ABC promotes sprouting of intact and injured spinal systems after spinal cord injury. J Neurosci. 2006;26:10856–67.

24. Bradbury EJ, Lawrence DFM, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002;416:36–40.

25. Dyck S, Kataria H, Alizadeh A, Santhosh KT, Lang B, Silver J, Karimi-Abdolrezaee S. Perturbing chondroitin sulfate proteoglycan signaling through LAR and PTPσ receptors promotes a beneficial inflammatory response following spinal cord injury. J Neuroinflammation. 2018;15.

26. Massey JM, Hubschner CH, Wagoner MR, Decke JA, Amps J, Silver J, Onifer SM. Chondroitinase ABC digestion of the perineuronal net promotes functional collateral sprouting in the cuneate nucleus after cervical spinal cord injury. J Neurosci. 2006;26:4406–14.

27. Siebert JR, Steizner DJ, Osterhout DJ. Chondroitinase treatment following spinal contusion injury increases migration of oligodendrocyte progenitor cells. Exp Neurol. 2011;231:19–29.

28. Kitagawa H, Shimakawa H, Sugahara K. The tumor suppressor EXT-like gene EXT2 encodes an α1,4-N-acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-acetylgalactosaminylglucosamine to the common glycosaminoglycan-protein linkage region. J Biol Chem. 1999;274:13933–7.

29. Keough MB, Jensen SK, Yong WW. Experimental demyelination and remyelination of murine spinal cord by focal injection of lyssolecithin. J Vis Exp. 2015;29:52679.

30. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214–9.

31. International Multiple Sclerosis Genetics Consortium. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353–60.

32. Nadaanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, Asano M, Kitagawa H. EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylene kinase-dependent manner. J Biol Chem. 2013;288:9321–33.

33. Kigeli KA, Gencel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2015;35:13435–44.

34. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keefe S, Phatnani HP, Guarnieri XP, Caneda C, Rudenisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Bessis A, Simons M, Meissner F, Prinz M, Kerschensteiner M, Jia X, Wu Q. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47.

35. Su AJ, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004;101(16):5062.

36. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo J, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–6.

37. Locatelli G, Theodorou D, Kendirli A, Iordache M, Staszewski O, Phulpagar K, Cantuti-Castelvetri L, Dalgalías A, Bessis A, Simons M, Meissner F, Prinz M, Kerschensteiner M. Mononuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model. Nat Neurosci. 2018;21:1196–208.

38. Luo T, Tran AP, Xin L, Sanapala C, Lang BT, Silver J, Yang Y. Modulation of proteoglycan receptor PTPσ enhances MMP-2 activity to promote recovery from multiple sclerosis. Nat Commun. 2018;9:4126.

39. Kucharcza K, Stallcup WB. NG2-proteoglycan-dependent contributions of oligodendrocyte progenitors and myeloid cells to myelin damage and repair. J Neuroinflammation. 2015;12.

40. Rolls A, Shechter R, London A, Segev Y, Jacob-Hirsch J, Amariglio N, Rechavi G, Schwartz M. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 2008;5:1262–77.

41. Canals L, Beneto N, Cozar M, Vilageliu L, Grinberg D. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome. Sci Rep. 2015;5.

42. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet. 2009;18:194–9.

43. Kuboyama K, Tanga N, Suzuki R, Fujikawa A, Noda M. Proteamine neutralizes chondroitin sulfate proteoglycan-mediated inhibition of oligodendrocyte differentiation. PLoS One. 2017;12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions